Antibiotic Utilization Patterns and Adverse Drug Events Risk in Special Populations A Comprehensive Review

Antibiotic utilization among special populations requires careful dose adjustment and monitoring, as these groups are at significantly higher risk for adverse drug events (ADEs) due to altered drug metabolism and underlying co-morbidities. Antibiotic stewardship is essential for managing special populations, as physiological changes in geriatric, pediatric and critically ill patients significantly alter drug pharmacokinetics and increase the risk of adverse drug events (ADEs). Data suggests high utilization of broad-spectrum agents in these groups, with geriatric patients accounting for over 45% of antibiotic-related ADEs and antibiotics driving nearly 50% of pediatric emergency room visits. Targeted, organ-specific pharmacovigilance and structured antimicrobial stewardship programs (ASPs) are necessary to mitigate these risks.Antibiotic utilization in special populations specifically the elderly, pediatrics and patients with renal/hepatic impairment is characterized by high consumption rates often coupled with irrational prescribing, leading to significant adverse drug events (ADEs). In these groups, Age-related pharmacokinetic (PK) and pharmacodynamic (PD) changes, polypharmacy and high comorbidity burden heighten the risk of severe, sometimes fatal, adverse events. 

Search Strategy (Methods)

"A systematic search was performed across PubMed/MEDLINE, Scopus and Web of Science databases for articles published between 2014 and 2024. Keywords used included 'Antibiotic Utilization,' 'Adverse Drug Events,' 'Special Populations,' 'Pediatric Pharmacotherapy,' 'Geriatric Antibiotic Use' and 'WHO AWaRe.' Inclusion criteria focused on randomized controlled trials, systematic reviews and large-scale observational studies reporting incidence rates of ADEs and utilization metrics (Eg; DDD per 1000 inhabitants)."

Pharmacological and Clinical Rationale

The use of antibiotics in special populations specifically the pediatric, geriatric and critically ill presents a complex challenge for clinicians. Unlike the general adult population, these groups exhibit significant variations in pharmacokinetics (PK) and pharmacodynamics (PD).

Pediatric Population: Antibiotics constitute over one-third of prescriptions, with high usage of broad-spectrum agents. Studies show up to 85% of antibiotics are prescribed inappropriately to children in some settings, often for respiratory infections. Key risks include disruption of the microbiome, increased risk of allergic diseases (atopic dermatitis, asthma) and obesity.Antibiotics cause nearly half of all drug-related emergency department visits for children. In infants (<1 year), the rate of ADEs per 10,000 prescriptions is the highest among all age groups. Specific risks include tooth discoloration (Tetracyclines) and potential cartilage damage (Fluoroquinolones).

Pediatric Considerations: Neonates and children are not "small adults." Their drug metabolism is governed by maturational changes in organ function, such as varying glomerular filtration rates (GFR) and hepatic enzyme activity. For instance, total body water is higher in infants, which increases the volume of distribution (????_????) for hydrophilic drugs like beta-lactams and aminoglycosides.

Geriatric Population (≥65 years): This group experiences the highest prevalence of antibiotic-related ADEs, accounting for approximately 45.6% of reported cases in some studies. This group receives a disproportionate number of antibiotics, often for prophylaxis or inappropriately for viral infections. Key risks include Clostridioides difficile infection (CDI), drug-induced delirium, renal toxicity (especially with Glycopeptides and Aminoglycosides) and severe cutaneous adverse reactions (cADRs), particularly with Sulfonamides and Cephalosporins, due to polypharmacy and impaired drug elimination.

Geriatric Considerations: Aging is associated with "inflammaging," increased frailty and progressive decline in renal and hepatic clearance. Elderly patients often present with multiple comorbidities, leading to polypharmacy and a heightened risk of drug-drug interactions (DDIs).

Critically Ill & Hospitalized Patients: Approximately 20% of hospitalized adults receiving antibiotics experience at least one ADE. Each additional day of therapy increases the odds of an ADE by roughly 4-7%.In the intensive care unit (ICU), patients often experience capillary leak syndrome or receive aggressive fluid resuscitation, which drastically increases the ????_???? of hydrophilic antibiotics, often leading to sub-therapeutic dosing and the emergence of antimicrobial resistance (AMR).

Patients with Co-morbidities: Individuals with chronic kidney disease (CKD) or liver disease have a significantly higher risk for antibiotic-induced organ damage. For example, those with advanced cancer have a 35% chance of developing an ADE when exposed to antibiotics.

Chronic Kidney Disease (CKD): Inadequate dosing (both under- and overdosing) is common due to reliance on creatinine-based estimations, which overestimates renal function. This leads to increased toxicity (overdose) or treatment failure (underdose).

Liver Disease: Impaired metabolism of lipophilic drugs and hypoalbuminemia (increasing free fractions of drugs) makes patients with liver dysfunction, such as cirrhosis, highly susceptible to ADEs from commonly used antibiotics. 

Risk Factors:

Polypharmacy: The risk of an ADR increases exponentially with the number of drugs; for example, from 13% with two medicines to 82% with seven or more.

Multiple Antibiotics: Taking more than one antibiotic concurrently doubles the risk of a serious ADR.

Inappropriate Prescribing: Roughly 50% of antibiotic prescriptions in pediatrics are estimated to be unnecessary or inappropriate, leading to avoidable toxicities. 

Major Adverse Drug Event (ADE) Patterns 

Cutaneous and Gastrointestinal: The skin and gastrointestinal systems are the most frequently affected, with rashes, pruritus and diarrhea being the most common ADRs.

Severe ADRs: These include acute renal failure (often with Aminoglycosides/Gentamicin), hepatotoxicity and severe skin reactions (Stevens-Johnson syndrome).

Neurotoxicity: ????-lactams (like Cefepime), Carbapenems and Metronidazole are associated with neurotoxic effects, including encephalopathy and seizures, particularly in the elderly. 

Table 1 Detailed Profile of Antibiotic Classes, Agents and Adverse Drug Events (ADEs)

Table 2 Pharmacokinetic Alterations and Clinical Implications

Table 3 Common Adverse Drug Events (ADEs) by Population

Utilization Patterns and the WHO AWaRe Framework

Current prescribing trends show an alarming reliance on the "Watch" group of antibiotics (Eg; Fluoroquinolones and 3^rdgeneration Cephalosporins), which are broad-spectrum and carry higher risks for resistance and ADEs. In many tertiary care settings, the Access-to-Watch ratio is significantly below the WHO target of 0.60, indicating widespread use of high-risk agents where narrower-spectrum alternatives might suffice.

DISCUSSION

Mitigating Risks through Precision Medicine - The high incidence of ADEs in special populations underscores the inadequacy of "one-size-fits-all" dosing. Precision medicine, through the integration of Therapeutic Drug Monitoring (TDM) and Pharmacogenomics (PGx), offers a pathway to optimize efficacy while minimizing toxicity. 

1. Therapeutic Drug Monitoring (TDM) - TDM is the clinical practice of measuring drug concentrations at designated intervals to maintain a constant concentration in a patient's bloodstream. This is non-negotiable for antibiotics with a narrow therapeutic index. 

Table 4 Antibiotics Requiring Routine TDM in Special Populations

2. Pharmacogenomics (PGx): Preventing Genetic Predispositions 

Pharmacogenomics identifies genetic variations that influence drug response. In special populations, especially pediatrics, genetic screening can prevent irreversible, life-altering adverse events. 

Aminoglycoside-Induced Hearing Loss: A specific mutation in the mitochondrial gene ????????−????????????1 (specifically the ????.1555???? > ???? variant) predisposes individuals to profound, permanent deafness even after a single dose of gentamicin.

Hypersensitivity Reactions: Testing for the ????????????−????*57?01 allele is now standard for Abacavir, but similar research is expanding into Sulfonamides and Penicillins to predict Stevens-Johnson Syndrome (SJS). 

3. Advanced Stewardship and Technology - Modern Antimicrobial Stewardship (AMS) programs are now utilizing technology to bridge the gap in clinical expertise. 

Antibiotic Stewardship: Promoting shorter treatment courses as short as clinically possible is the most effective way to reduce the cumulative risk of ADEs.

Point-of-Care Testing (POCT): Utilizing rapid biomarkers like Procalcitonin (PCT) and C-reactive protein (CRP) to differentiate between bacterial and viral infections, thereby preventing unnecessary antibiotic exposure in pediatric and geriatric patients.

AI-Driven Dosing: Software (Eg; InsightRX, DoseMeRx) uses Bayesian forecasting to predict the best dose for a specific patient based on their age, weight and renal function in real-time. 

Summary of Findings 

ADR Incidence: Studies report ADR incidence rates for antibiotics to be roughly 14–16% among hospitalized patients.

Highest Risk Antibiotics: Cephalosporins, Fluoroquinolones and ????-lactam combinations are frequently cited as causing the highest rates of ADRs in these populations.

Conclusion: Regular monitoring for early detection of ADEs and strict adherence to guidelines can prevent a significant percentage of antibiotic-related hospital admissions. 

Table 5 Summary of Preventative Strategies

Table 6 Comprehensive Adverse Event Profiles by Antibiotic Class